Qualifying and Outcome Strokes in the RESPECT PFO Trial: Additional Evidence of Treatment Effect
|
|
- Lucas Summers
- 5 years ago
- Views:
Transcription
1 Qualifying and Outcome Strokes in the RESPECT PFO Trial: Additional Evidence of Treatment Effect JEFFREY L. SAVER, MD DAVID E. THALER, MD, PHD, RICHARD W. SMALLING, MD, PHD, JOHN D. CARROLL, MD, SCOTT BERRY, PHD, LEE A. MACDONALD, MD, DAVID S. MARKS, MD, MBA, DAVID L. TIRSCHWELL, MD, DIANE BOOK, MD, LARRY B. GOLDSTEIN, MD, BRIAN LARKIN, MD and THE RESPECT INVESTIGATORS
2 Disclosure Statement of Financial Interest Author J.L. Saver Disclosure Employment -University of California, which received clinical trial research funds and payments for consulting professional services from St. Jude Medical; Significant D. Thaler Research Grant; Modest; St. Jude Medical. Consultant/Advisory Board; Modest; St. Jude Medical R. Smalling Research Grant; Modest; St. Jude Medical. Consultant/Advisory Board; Modest; St. Jude Medical J. Carroll Research Grant; Modest; St. Jude Medical. Consultant/Advisory Board; Modest; St. Jude Medical S. Berry Consultant/Advisory Board; Modest; St. Jude Medical L. MacDonald Research Grant; Modest; St. Jude Medical. Consultant/Advisory Board; Modest; St. Jude Medical D. Marks Research Grant; Modest; St. Jude Medical. Consultant/Advisory Board; Modest; St. Jude Medical D. Tirschwell Research Grant; Modest; St. Jude Medical. Consultant/Advisory Board; Modest; St. Jude Medical D. Book Research Grant; Modest; St. Jude Medical. Consultant/Advisory Board; Modest; St. Jude Medical L.B. Goldstein Research Grant; Modest; St. Jude Medical. Consultant/Advisory Board; Modest; St. Jude Medical B. Larkin Consultant/Advisory Board; Modest; St. Jude Medical 2
3 Background: Cryptogenic Stroke and PFO Cryptogenic stroke remains a major challenge PFO-related strokes, i.e. due to paradoxical embolism, have been strongly implicated as a possible cause Patients age are now a larger percentage of all stroke patients and among first ever strokes in the younger population there is growth in ischemic strokes 1 Cost of stroke is significant, with over $94B 2,3 spent each year in the US and EU alone cost implications with young patients are immense, based on the loss of productivity and long-term care The results of PFO closure trials have included positive observational studies and one neutral randomized trial The RESPECT trial was designed with a well-defined stroke population, a statistical design appropriate for expected low recurrent event rates, and used a device with an excellent safety record 1. Kissela, BM, Khoury, JC, Alwell, K,et al. Age at stroke Temporal trends in stroke incidence in a large, biracial population. Neurology 2012;79: Roger, V, Go, A, Lloyd-Jones, D, et. Al. Heart Disease and Stroke Statistics 2012 Update: A Report from the American Heart Association. Circulation. 2012; 125:e2-e Allender,S, Scarborough, P, Peto, V, et al European cardiovascular disease statistics *CAUTION: Investigational device in the United States. Limited by Federal (or U.S.) law to investigational use. Not available for sale in the U.S.
4 1. P-values ITT Raw Count are calculated using Fisher s Exact Test; all other P-values are calculated Log-Rank Test RESPECT Efficacy Analyses 46.6%-72.7% risk reduction of stroke in favor of device Totality of Evidence 46.6% % risk reduction of stroke in favor of device Primary Endpoint Analyses ITT Cohort 50.8% risk reduction of stroke in favor of device Analysis Risk Reduction P-value 1 Intent to Treat Raw Count 46.6% Intent to Treat KM 50.8% Per Protocol KM 63.4% As Treated KM 72.7% Primary Endpoint Analyses PP Cohort 63.4% risk reduction of stroke in favor of device Primary Endpoint Analyses AT Cohort 72.7% risk reduction of stroke in favor of device 4
5 Objective To characterize the qualifying ischemic strokes in the RESPECT Trial To characterize the endpoint ischemic strokes in the RESPECT Trial 5
6 Methods: Trial Design Design Multicenter: 69 Sites (62 US, 7 Canada) Prospective, 1:1 Randomized stratified by site and atrial septal aneurysm Device Group (Test): Closure with the AMPLATZER TM PFO Occluder plus medical therapy Medical Group (Control): 5 Medical Treatment Regimens: Aspirin Clopidogrel Warfarin Aspirin with dipyridamole Aspirin with clopidogrel 1 Sample Size: Event-driven continued enrollment until 25 th endpoint Primary Analyses Trial Status Sponsor Four protocol-specified analyses with raw count primary analysis Trial was conducted under an Investigational Device Exemption (IDE) St. Jude Medical, St. Paul, MN *Study initiated under AGA Medical, Plymouth, MN 6 1. Aspirin with clopidogrel was removed from the protocol in 2006 based on changes to the AHA/ASA treatment guidelines
7 Study Governance and Organization Executive Steering Committee John D. Carroll, MD, University of Colorado/University of Colorado Hospital, Department of Medicine (Cardiology) Jeffrey L. Saver, MD, University of California, Los Angeles, Department of Neurology Richard W. Smalling, MD, PhD, University of Texas/Memorial Hermann Heart and Vascular Institute, Division of Cardiology David E. Thaler, MD, PhD, Tufts University/ Tufts Medical Center, Department of Neurology Independent Review Independent Clinical Events Committee (CEC) Independent Data Safety and Monitoring Board (DSMB) Independent Neurological Executive Committee Core Laboratories: Hematology (Quintiles) Echocardiography (CVR Consulting, PC) Statistical Oversight Independent Biostatistician: Berry Consultants 7
8 Inclusion/Exclusion Criteria Inclusion Criteria: Patients (ages 18 to 60) with PFO who have had a cryptogenic stroke within 270 days Stroke defined as acute focal neurological deficit, presumed to be due to focal ischemia, and either symptoms persisting 1) 24 hours, or 2) < 24 hours with MR or CT confirmed new, neuroanatomically relevant, cerebral infarct PFO defined as TEE visualization of micro-bubbles in the left atrium within 3 cardiac cycles of their appearance in the right atrium at rest and/or during Valsalva release Key Exclusion Criteria: Cerebral, cardiovascular, and systemic conditions that suggest other mechanisms for stroke. Examples: Carotid disease, atrial fibrillation, cardiomyopathy, etc. Arterial hypercoagulable states Contraindications: To aspirin or clopidogrel Uncontrolled diabetes mellitus or hypertension Other sources of right to left shunt Anatomical to device placement Any other reason to expect limited life expectancy, inability to attend follow-up visits, or inability to provide informed consent 8
9 RESPECT Entry Criteria Ischemic Stroke, not TIA Ischemic stroke: acute focal neurological deficit, presumed to be due to focal ischemia, and either: Symptoms persisting 24 hours or greater, or Symptoms persisting less than 24 hours but associated with MR or CT findings of a new, neuroanatomically relevant, cerebral infarct 9
10 RESPECT Entry Criteria Stroke Mechanism Inclusion criteria Age Exclusion criteria Arteriopathy Atherosclerosis or other arteriopathy of intracranial or extracranial vessels >50% supplying the involved lesion Aortic arch plaque > 4 mm into the lumen Arterial dissection as qualifying event Cardioembolic source A fib/flutter chronic/intermittent; Intracardiac thrombus or tumor; MI within last 6 mos; LV aneurysm or akinesis; Mitral or aortic valve vegetation or prosthesis; LVEF < 35%; Endocarditis Arterial hypercoagulable state Antiphospholipid Abs, Homocysteinemia Lacunar infarct probably due to intrinsic small vessel disease 10
11 Key Exclusion - Lacunar Infarct Probably Due to Intrinsic Small Vessel Disease Ischemic stroke in the distribution of a single, small, deep penetrating vessel AND ANY of the following: HTN (except in 1 st week post stroke) DM Age 50 MRI or CT shows leukoaraiosis greater than symmetric, well-defined periventricular caps or bands (European Task Force on Age-Related White Matter Changes rating scale score > 0) Wahlund LO et al, Stroke 2001
12 Etiologic Analysis: A-S-C-O-D Stroke Classification System* - Atherosclerosis - Other - Small Vessel Disease - Dissection - Cardiac Source --Amarenco et al, CVD 2009; Amerenco personal correspondence 2013, Delewi et al, Eur J Radiol 2012, Johari et al, Dis Mon 2012, Mathey et al, Circulation 2010 * Modified only in that presence of a PFO did not classify patients in a cardiac source category 0 Disease not detected 1 - Definitely a potential cause 2 - Present, causal link uncertain 3 - Present, unlikely a cause 9 - Testing not performed 12
13 Study Results Qualifying Strokes 13
14 Qualifying Ischemic Stroke Timing and Severity No difference between groups Device Group N=499 Medical Group N=481 All Subjects N=980 P- value Characteristic Days from stroke to 130 (70) 130 (69) 130 (70) 0.89 randomization a NIHSS 0 (0 1) 0 (0 1) 0 (0 1) stroke deficit score b Barthel Index 100 ( ) ( ) ( ) ADL score b mrs disability score b 1 (0 1) 1 (0 1) 1 (0 1) a. Data represented as mean (standard deviation) for months from randomization to event b. Data presented in terms of median (interquartile range) for NIHSS, Barthel and mrs. 14
15 Topography of Qualifying Ischemic Stroke Well balanced between groups Topography Device Group N=442 Medical Group N=448 All Subjects N=890 Superficial Only 53.8% 52.7% 53.3% Mixed Superf - Deep 9.5% 7.4% 8.4% Large Deep Only 4.1% 4.5% 4.3% Small Deep Only 12.9% 15.6% 14.3% Other 19.7% 19.9% 19.8% P- value a 0.64 a. P-values calculated using Chi-Squared Test 15
16 Lesion Size of Qualifying Ischemic Infarcts Larger lesions in almost 50% of subjects Lesion size Device Group N=443 Medical Group N=446 All Subjects N=889 Small (<0.5 cm) 17.6% 20.6% 19.1% Intermediate ( cm) 33.0% 31.2% 32.1% Moderate ( cm) 19.9% 28.5% 24.2% P-value a Large ( cm) 24.4% 16.6% 20.5% Massive (>6.0 cm) 5.2% 3.1% 4.2% Larger ( 1.5 cm) 49.4% 48.2% 48.8% 0.71 b a. P-values calculated using Mann-Whitney-Wilcoxon Test b. P-values calculated using Fisher s Exact test 16
17 Subpopulation Differential Treatment Effect P=
18 Study Results Endpoint Strokes 18
19 Endpoint Ischemic Stroke Timing and Severity Characteristic Months from randomization to event Device Group n=9 16 (22.4) Medical Group n= (15.5) All Subjects n= (17.9) P-value a NIHSS 2 (2-3) 2 (0-4) 2 (0-4) 0.70 stroke deficit score b Barthel Index 100 (95-100) 100 (85-100) 100 (90-100) 0.59 ADL score b mrs 1 (1-3) 1 (0-2) 1 (0-3) 0.56 disability score b 0.38 a. P-values calculated using Mann-Whitney-Wilcoxon test b. Data presented in terms of median (interquartile range) for NIHSS, Barthel and mrs. Data represented as mean (standard deviation) for months from randomization to event 19
20 Topography of Endpoint Ischemic Strokes Superficial and other infarcts were more common in the Medical Group Topography Device Group n=7 Medical Group n=13 All Subjects n=20 Superficial Only 57.1% 61.5% 60% P-value a Mixed Superf - Deep 0.0% 15.4% 10% Large Deep Only 0.0% 0.0% 0.0% Small Deep Only 42.9% 0.0% 15% 0.04 Other 0.0% 23.1% 15% a. P-values calculated using Chi-Squared Test 20
21 Lesion Size of Endpoint Ischemic Strokes Recurrent larger infarcts were more frequent in the Medical Group at 69.2% vs. 14.3% in the Device Group Lesion size Device Group n=7 Medical Group n=13 All Subjects n=20 Small (<0.5 cm) 42.9% 23.1% 30% P-value Intermediate ( cm) 42.9% 7.7% 20% Moderate ( cm) 0.0% 30.8% 20% Large ( cm) 14.3% 15.4% 15% 0.09 a Massive (>6.0 cm) 0.0% 23.1% 15% Larger ( 1.5 cm) 14.3% 69.2% 50% 0.06 b a. P-values calculated using Mann-Whitney-Wilcoxon Test b. P-values calculated using Fisher s Exact test 21
22 Number Lesion Size of Endpoint Ischemic Strokes Recurrent Medical Group infarcts overall were larger Device Medical 0 Small Intermediate Moderate Large Massive Increasing Infarct Size --> 22
23 A-S-C-O-D Stroke Subtype Classification Cryptogenic stroke 9 in Medical Group vs. 4 in Device Group Mechanism Definite potential non-pfo Present, uncertain causality Cryptogenic, complete w/up Cryptogenic, incomplete w/up Device Group n=9 Medical Group n=16 n / (%) Details n / (%) Details Radiation arteriopathy - 1 Atrial fibrillation 3 2 (22%) 4 (25%) SLE + SVD - 1 SVD - 1 Dissection - 1 Atherothrombosis 2 3 (33%) 3 (19%) Atherothrombosis - 1 Post-ICH evacuation 1 SVD (33%) 6 (37%) 1 (11%) 3 (19%) 23
24 Stroke Mechanism Aspects of Endpoint Ischemic Strokes Device Arm 3 of the 9 device arm ischemic strokes occurred in patients without a device in place 1 after randomization but prior to PFO occluder implant 1 in patient who declined procedure and crossed to medical therapy 1 in patient who required a CABG after randomization but prior to study procedure and who underwent bovine pericardium patch PFO repair during the surgery instead of device closure Of the remaining 6 device arm ischemic strokes 2 had alternative causes evident (SLE, radiation) 2 were small, deep only infarcts 24
25 Discussion The RESPECT population was stringently selected to identify patients with cryptogenic ischemic stroke Frequency of recurrent strokes due to a defined mechanism other than PFO was low 6 over 2559 follow-up years - 0.2% per patient year The exclusion of small deep infarcts likely due to intrinsic small vessel disease was successful in limiting recurrent small deep infarcts as endpoint events The types of infarcts particularly averted in the device group were those associated with paradoxical embolic stroke mechanism Superficial vascular distribution Large infarct size In ITT analysis, event rate was low in medical arm (1.25% per patient-year) but even lower in device arm (0.61% per patient-year) 25
26 Limitations Subgroup interaction analysis with only 25 events is exploratory in nature Clinically, the atrial septal aneurysm, shunt size, and superficial topography findings are relevant and support mechanism of action Work-up of endpoint events incomplete in some cases Some occurred at non-study centers All occurred in patients who had already had a complete work up for qualifying infarcts 26
27 Conclusions Consideration of neurovascular aspects of the RESPECT trial reinforce the primary analysis With stringent patient selection to identify patients with a history of cryptogenic stroke and PFO, closure with the AMPLATZER PFO Occluder showed evidence of benefit over medical management alone Indications of magnified effect in averting superficial cerebral infarcts and larger cerebral infarcts provide additional evidence of a genuine biological effect of closure with the AMPLATZER PFO Occluder in preventing recurrent cerebral infarcts due to paradoxical emboli 27
28 Study Sites and Principal Investigators 28
29 Trial Sites Top 5 enrollers noted 29
Effect of Having a PFO Occlusion Device in Place in the RESPECT PFO Closure Trial
Effect of Having a PFO Occlusion Device in Place in the RESPECT PFO Closure Trial DAVID E. THALER, MD, PHD, JEFFREY L. SAVER, MD RICHARD W. SMALLING, MD, PHD, JOHN D. CARROLL, MD, SCOTT BERRY, PHD, LEE
More informationPFO Management update
PFO Management update May 12, 2017 Peter Casterella, MD Swedish Heart and Vascular 1 PFO Update 2017: Objectives Review recently released late outcomes of RESPECT trial and subsequent FDA approval of PFO
More informationUpdate interventional Cardiology Hans Rickli St.Gallen
Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter
More informationTrue cryptogenic stroke
True cryptogenic stroke Arne Lindgren, MD, PhD Dept of Clinical Sciences Lund, Neurology, Lund University Dept of Neurology and Rehabilitation Medicine Skåne University Hospital Lund, Sweden Disclosures
More informationDEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE. Matthew Starr, MD Stroke Attending
DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE Matthew Starr, MD Stroke Attending DISCLOSURES None DEBATE Should PFO be closed? * * Sometimes yes THE CASE AGAINST PFO CLOSURE 1. Did the PFO cause the
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More information2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.
CRYPTOGENIC STROKE: 2017 Cardiovascular Symposium A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A. CRYPTOGENIC STROKE CRYPTOGENIC: OF OBSCURE OR UNKNOWN
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationPatent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS
Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS 11-8-18 Outline 1. Background 2. Anatomy of patent foramen ovale (PFO) 3. Relationship between PFO and
More informationCryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare
Cryptogenic Stroke: What Don t We Know Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare Financial Disclosures None Objectives Principles of diagnostic evaluation
More informationWhy Should We Treat PFO?
Why Should We Treat PFO? SCAI Interventional Cardiology Fellows Course December 7, 2012 Jonathan Tobis, MD Director of Interventional Cardiology UCLA Disclosures Jonathan Tobis, MD 1. A Principal Investigator
More informationRahul Jhaveri, M.D. The Heart Group of Lancaster General Health
Rahul Jhaveri, M.D. The Heart Group of Lancaster General Health INTRODUCTION Three recently published randomized controlled trials in The New England Journal of Medicine provide new information about closure
More informationΣΥΓΚΛΕΙΣΗ ΑΝΟΙΚΤΟΥ ΩΟΕΙΔΟΥΣ ΤΡΗΜΑΤΟΣ ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC 33 Ο Πανελλήνιο Καρδιολογικό Συνζδριο ΑΘΗΝΑ 2012
ΣΥΓΚΛΕΙΣΗ ΑΝΟΙΚΤΟΥ ΩΟΕΙΔΟΥΣ ΤΡΗΜΑΤΟΣ 2012 ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC 33 Ο Πανελλήνιο Καρδιολογικό Συνζδριο ΑΘΗΝΑ 2012 The Problem: Not All PFO in Patients With Cryptogenic Stroke is Pathogenic; No Definitive
More informationRESPECT Safety Findings
CO-1 SCAI Town Hall Meeting Monday, October 31, 2016 Washington, DC RESPECT Safety Findings John D. Carroll, M.D., MSCAI Professor of Medicine Cardiology University of Colorado School of Medicine University
More informationI, (Issam Moussa) DO NOT have a financial interest/arrangement t/ t or affiliation with one or more organizations that could be perceived as a real
PFO Closure: Where We Are Going to after CLOSURE I Study? Issam D. Moussa, MD Professor of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida Disclosure Statement of
More informationPatent Foramen Ovale: Diagnosis and Treatment
Patent Foramen Ovale: Diagnosis and Treatment Anthony DeMaria Judy and Jack White Chair in Cardiology University of California, San Diego At one time or another a Grantee, Sponsored Speaker or Ad-hoc Consultant
More informationDirect oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece
Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece Disclosures Scholarships: European Stroke Organization; Hellenic Society of Atherosclerosis.
More informationPatent foramen ovale (PFO) is composed of
PFO Closure for Prevention of Recurrent Cryptogenic Stroke The evidence base is here. BY JOHN F. RHODES, JR, MD Patent foramen ovale (PFO) is composed of overlapping portions of septum primum and septum
More informationManagement and Investigation of Ischemic Stroke By Etiology
Management and Investigation of Ischemic Stroke By Etiology Andrew M. Demchuk MD FRCPC Director, Calgary Stroke Program Deputy Dept Head, Clinical Neurosciences Heart and Stroke Foundation Chair in Stroke
More informationStroke Case Studies. Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow
Stroke Case Studies Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow Case 1 64 year old female with dysphasia and right arm weakness 3 hours prior CT head: dense M1 sign. No established ischaemia
More informationEAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC
EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism Luigi P. Badano, MD, FESC Background Stroke is the 3 cause of death in several industrial countries; Embolism accounts for 15-30%
More informationWhy Treat Patent Forman Ovale
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural Heart Disease Rush University Medical Center Conclusions
More information[(PHY-3a) Initials of MD reviewing films] [(PHY-3b) Initials of 2 nd opinion MD]
2015 PHYSICIAN SIGN-OFF (1) STUDY NO (PHY-1) CASE, PER PHYSICIAN REVIEW 1=yes 2=no [strictly meets case definition] (PHY-1a) CASE, IN PHYSICIAN S OPINION 1=yes 2=no (PHY-2) (PHY-3) [based on all available
More informationHow to Evaluate Patients with Cryptogenic Stroke
How to Evaluate Patients with Cryptogenic Stroke Jeffrey Saver, MD Professor of Neurology Director, How to Evaluate Patients with Cryptogenic Stroke Disclosure Scientific Consultant, Unpaid Trialist: AGA
More informationFabien Praz, Andreas Wahl, Sophie Beney, Stephan Windecker, Heinrich P. Mattle*, Bernhard Meier
Procedural Outcome after Percutaneous Closure of Patent Foramen Ovale using the Amplatzer PFO Occluder Without Intra-Procedural Echocardiography in 1,000 Patients Fabien Praz, Andreas Wahl, Sophie Beney,
More informationHow Can We Properly Manage Patients With Stroke of Undetermined Origin?
How Can We Properly Manage Patients With Stroke of Undetermined Origin? : Spotlight on Embolic Stroke of Undetermined Source (ESUS) MI SUN OH Department of Neurology, Hallym University Scared Heart Hospital,
More informationCLOSE. Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence
CLOSE Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence Guillaume TURC, MD, PhD Paris Descartes University Sainte-Anne hospital Paris, France On
More informationSpeakers. 2015, American Heart Association 1
Speakers Lee Schwamm, MD, FAHA Executive Vice Chairman of Neurology, Massachusetts General Hospital Director, Stroke Service and Medical Director, MGH TeleHealth, Massachusetts General Hospital Director,
More informationPFO closure group total no. PFO closure group no. of males
Suppl Table. Characteristics of the five trials included in this meta-analysis. Trial name Device used for Definition of medical Primary Endpoint group total no. group no. of males group age (yrs) group
More informationCLINICAL FEATURES THAT SUPPORT ATHEROSCLEROTIC STROKE 1. cerebral cortical impairment (aphasia, neglect, restricted motor involvement, etc.) or brain stem or cerebellar dysfunction 2. lacunar clinical
More informationACUTE CENTRAL PERIFERALEMBOLISM
EAE TEACHING COURSE 2010 Belgrade, Serbia October 22-23, 2010 ACUTE CENTRAL and PERIFERALEMBOLISM Maria João Andrade Lisbon, PT BACKGROUND Stroke is a leading cause of mortality and long-term disability
More informationCryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?
Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do? Robert J. Sommer, MD Columbia University Medical Center New York, NY Disclosure Statement of Financial Interest Within the past
More informationGERIATRICS CASE PRESENTATION
GERIATRICS CASE PRESENTATION CASE 79 year old Patient X was admitted to hospital with SOB. He had a hx of sarcoidosis and asbestosis. Home oxygen requirement is 3-3.5litre. He was admitted, given ceftriaxone
More informationStroke and ASA / FO REBUTTAL
REBUTTAL Definition of an ischemic stroke Definition of a PFO Evidence for a causal role of PFO in stroke Evidence against a role of PFO in stroke Stroke recurrencies in stroke (PFO) patients Medical treatment
More information/ / / / / / Hospital Abstraction: Stroke/TIA. Participant ID: Hospital Code: Multi-Ethnic Study of Atherosclerosis
Multi-Ethnic Study of Atherosclerosis Participant ID: Hospital Code: Hospital Abstraction: Stroke/TIA History and Hospital Record 1. Was the participant hospitalized as an immediate consequence of this
More informationPercutaneous closure of a patent foramen ovale after cryptogenic stroke
Neth Heart J (2018) 26:5 12 https://doi.org/10.1007/s12471-017-1063-3 POINT OF VIEW Percutaneous closure of a patent foramen ovale after cryptogenic stroke R. J. R. Snijder 1 M.J.Suttorp 1 J.M.tenBerg
More informationCEREBRO VASCULAR ACCIDENTS
CEREBRO VASCULAR S MICHAEL OPONG-KUSI, DO MBA MORTON CLINIC, TULSA, OK, USA 8/9/2012 1 Cerebrovascular Accident Third Leading cause of deaths (USA) 750,000 strokes in USA per year. 150,000 deaths in USA
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
More informationPATENT FORAMEN OVALE: UPDATE IN MANAGEMENT OF RECURRENT STROKE KATRINE ZHIROFF, MD, FACC, FSCAI LOS ANGELES CARDIOLOGY ASSOCIATES
PATENT FORAMEN OVALE: UPDATE IN MANAGEMENT OF RECURRENT STROKE KATRINE ZHIROFF, MD, FACC, FSCAI LOS ANGELES CARDIOLOGY ASSOCIATES OBJECTIVES Review social burden and epidemiology of stroke Gender disparities
More information2018 Update in Diagnosis and Management of Stroke
2018 Update in Diagnosis and Management of Stroke S. Andrew Josephson MD Carmen Castro Franceschi and Gladyne K. Mitchell Neurohospitalist Distinguished Professor Chair, Department of Neurology Director,
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationThrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE
Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE ESUS Progression of haematoma Anticoagulation Large ICH
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationIn October 2016, the US Food and Drug Administration
The Approval of PFO Closure in the United States A look back at the long road to FDA approval and the implications on patient care options going forward. By Marie-France Poulin, MD, and Clifford J. Kavinsky,
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationSixth Annual Intensive Update in Neurology 9/15-16/2016. W Tom Kushner DO Swedish Stroke Clinic Neurohospitalist
W Tom Kushner DO Swedish Stroke Clinic Neurohospitalist 1 One Strategy for cryptogenic stroke: ESUS Positively defined criteria FDA allows clinical trials NOACs have lower risk profile Another strategy
More information2015 Update in Diagnosis and Management of Stroke
2015 Update in Diagnosis and Management of Stroke S. Andrew Josephson MD Carmen Castro Franceschi and Gladyne K. Mitchell Neurohospitalist Distinguished Professor Senior Executive Vice Chair, Department
More informationPermanent foramen ovale: when to close?
Permanent foramen ovale: when to close? Pierre Amarenco INSERM U-698 and Denis Diderot University - Paris VII Department of Neurology and Stroke Center Bichat hospital, Paris, France PFO - Pathology TEE
More informationIschemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
More informationNIH Public Access Author Manuscript J Stroke Cerebrovasc Dis. Author manuscript; available in PMC 2008 September 1.
NIH Public Access Author Manuscript Published in final edited form as: J Stroke Cerebrovasc Dis. 2007 ; 16(5): 216 219. Echocardiography in Patients with Symptomatic Intracranial Stenosis Scott E. Kasner,
More informationAntithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
More informationCryptogenic Strokes: Evaluation and Management
Cryptogenic Strokes: Evaluation and Management 77 yo man with hypertension and hyperlipidemia developed onset of left hemiparesis and right gaze preference, last seen normal at 10:00 AM Brought to ZSFG
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Hart RG, Diener H-C, Coutts SB, et al,
More informationPFO- To Close for Comfort. By: Vincent J.Caracciolo, MD FACC
PFO- To Close for Comfort By: Vincent J.Caracciolo, MD FACC PATENT FORAMEN OVALE PFO- congenital lesion that frequently persists into adulthood ( 25-30%)- autopsy and TEE studies. PFO prevalence higher
More informationEvidence Based Stroke Update Ajay Bhalla Guy s and St Thomas Hospitals UK Stroke Forum
Evidence Based Stroke Update 2017 Ajay Bhalla Guy s and St Thomas Hospitals UK Stroke Forum Future is hard to predict.. Future is hard to predict.. Future is hard to predict.. Future is hard to predict..
More informationAVC Criptogénico: Está na altura de alterar as guidelines? Claudia Jorge University Hospital of Santa Maria
Está na altura de alterar as guidelines? Claudia Jorge University Hospital of Santa Maria Está na altura de alterar as guidelines? Está na altura de alterar as guidelines? ~25% of all ischemic strokes
More information12/4/2017. Disclosures. Study organization. Stryker Medtronic Penumbra Viz Route 92. Data safety monitoring board Tudor G.
12/4/2017 Update on Stroke Trials:Extending the Window DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo NP001713
More informationLong-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
The new england journal of medicine Original Article Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke Jeffrey L. Saver, M.D., John D. Carroll, M.D., David E. Thaler, M.D.,
More informationCAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough
Todd W GenslerMD April 28, 2018 CAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough DISCLOSURES I have no financial disclosures Presenter name
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationDevices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
More informationTIA: Updates and Management 2008
TIA: Updates and Management 2008 S. Andrew Josephson, MD Department of Neurology, Neurovascular Division University of California San Francisco Commonly Held TIA Misconceptions TIA is easy to diagnose
More informationNon-commercial use only
Italian Journal of Medicine 2016; volume 10:202-206 Embolic stroke of undetermined source: a retrospective analysis from an Italian Stroke Unit Marco Masina, 1 Annalena Cicognani, 1 Carla Lofiego, 2 Simona
More informationPERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
More informationWhen Should I Order a Stress Test or an Echocardiogram
When Should I Order a Stress Test or an Echocardiogram Updates in Cardiology 2015 March 7, 2015 Donald L. Lappé, MD, FAHA, FACC Chairman, Cardiovascular Department Medical Director, Intermountain Cardiovascular
More informationStroke 101. Maine Cardiovascular Health Summit. Eileen Hawkins, RN, MSN, CNRN Pen Bay Stroke Program Coordinator November 7, 2013
Stroke 101 Maine Cardiovascular Health Summit Eileen Hawkins, RN, MSN, CNRN Pen Bay Stroke Program Coordinator November 7, 2013 Stroke Statistics Definition of stroke Risk factors Warning signs Treatment
More informationCritical Review Form Therapy
Critical Review Form Therapy A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects, Lancet-Neurology 2007; 6: 953-960 Objectives: To evaluate the effect of
More informationTranscatheter closure of patent foramen ovale using the internal jugular venous approach
New methods in diagnosis and therapy Transcatheter closure of patent foramen ovale using the internal jugular venous approach Przemysław Węglarz 1,2, Ewa Konarska-Kuszewska 2, Tadeusz Zębik 2, Piotr Kuszewski
More informationCerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR)
Cerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR) Michael Mack, MD, Michael Acker, MD, Steve Messe, MD For the Cardiothoracic Surgical Trials Network (CTSN) American
More informationNew Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008
New Trials in Progress: ACT 1 Jon Matsumura, MD Cannes, France June 28, 2008 Faculty Disclosure I disclose the following financial relationships: Consultant, CAS training director, and/or research grants
More informationMEET 2007: Evaluation and treatment of the stroke and TIA patient for the non-neurointerventionist. neurointerventionist
MEET 2007: Evaluation and treatment of the stroke and TIA patient for the non-neurointerventionist neurointerventionist Steve Ramee, MD Ochsner Medical Center New Orleans DISCLOSURE Nothing Nothing to
More informationIntroducing the COAPT Trial
physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing
More informationAdvances in Prevention and Treatment of Stroke: What Every Primary Care Physician Needs to Know. Case 1 4/5/11. What treatment should you initiate?
Advances in Prevention and Treatment of Stroke: What Every Primary Care Physician Needs to Know S. Andrew Josephson, MD Director, Neurohospitalist Program Medical Director, Inpatient Neurology University
More informationClinical Policy: Transcatheter Closure of Patent Foramen Ovale Reference Number: CP.MP.151
Clinical Policy: Reference Number: CP.MP.151 Effective Date: 12/17 Last Review Date: 12/17 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications
More informationEarly and One-year Outcomes of Aortic Root Surgery in Marfan Syndrome Patients
Early and One-year Outcomes of Aortic Root Surgery in Marfan Syndrome Patients A Prospective, Multi-Center, Comparative Study Joseph S. Coselli, Irina V. Volguina, Scott A. LeMaire, Thoralf M. Sundt, Elizabeth
More informationStroke Update. Claire J. Creutzfeldt, MD January 12, 2018
Stroke Update Claire J. Creutzfeldt, MD January 12, 2018 Disclosures None relevant to this presentation I receive funding from the NINDS What s new in stroke? A new model for cardioembolic stroke: atrial
More informationTCT mdbuyline.com Clinical Trial Results Summary
TCT 2012 Clinical Trial Results Summary FAME2 Trial: FFR (fractional flow reserve) guided PCI in all target lesions Patients with significant ischemia, randomized 1:1 Control arm: not hemodynamically significant
More informationAlan Barber. Professor of Clinical Neurology University of Auckland
Alan Barber Professor of Clinical Neurology University of Auckland Presented with L numbness & slurred speech 2 episodes; 10 mins & 2 hrs Hypertension Type II DM Examination pulse 80/min reg, BP 160/95
More informationSJM-AMPLP (2) Item approved for U.S. only.
SUMMARY OF CLINICAL EVIDENCE Patent Foramen Ovale closure with the Amplatzer PFO Occluder for secondary stroke reduction of risk in patients with cryptogenic stroke 1 THE HEALTH PROBLEM A patent foramen
More informationAntithrombotic Summit Basel 2012 Basel, 26. April Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel
Antithrombotic Summit Basel 2012 Basel, 26. April 2012 Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel Background stroke = third-leading cause of death among adults 1/5 of stroke survivors require
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationINSTRUCTIONS FOR USE FOR:
INSTRUCTIONS FOR USE FOR: en English bg INSTRUCTIONS FOR USE FOR: GORE CARDIOFORM SEPTAL OCCLUDER Carefully read all instructions prior to use. Observe all warnings and precautions noted throughout these
More informationTranscatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT
Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT and Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac
More informationShawke A. Soueidan, MD. Riverside Neurology & Sleep Specialists
Shawke A. Soueidan, MD Riverside Neurology & Sleep Specialists 757-221-0110 Epidemiology of stroke 2018 Affects nearly 800,000 people in the US annually Approximately 600000 first-ever strokes and 185000
More information(LAA Closure & PFO Closure)
18th ANGIOPLASTY SUMMIT-TCTAP 2013 Seoul, Korea, April 23-26, 2013 Review Year and Future To Closure or Not to Close (LAA Closure & PFO Closure) Horst Sievert CardioVascular Center Frankfurt - CVC Frankfurt,
More informationEchocardiography in Systemic Embolization. January 29, 2007 Joe M. Moody, Jr, MD UTHSCSA and STVHCS
Echocardiography in Systemic Embolization January 29, 2007 Joe M. Moody, Jr, MD UTHSCSA and STVHCS Neurologic Events and Cardiac Source of Embolus For patients who present with evidence of abrupt arterial
More informationCatheter-based mitral valve repair MitraClip System
Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular
More informationThe Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging
The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging REBECCA F. GOTTESMAN, MD PHD ASSOCIATE PROFESSOR OF NEUROLOGY AND EPIDEMIOLOGY JOHNS HOPKINS UNIVERSITY OCTOBER 20, 2014 Outline
More informationAPOLLO TMVR Trial Update: Case Presentation
APOLLO TMVR Trial Update: Case Presentation Anelechi Anyanwu, MD, MSc, FRCS-CTh Professor and Vice-Chairman Department of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Disclosure
More informationCPAG Summary Report for Clinical Panel Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke The Benefits of the Proposition Percutaneous Patent Foramen Ovale
More informationManagement of intracranial atherosclerotic stenosis (ICAS)/intracranial atherosclerosis
Management of intracranial atherosclerotic stenosis (ICAS)/intracranial atherosclerosis Tim Mikesell, D.O. Oct 22, 2016 Stroke facts Despite progress in decreasing stroke incidence and mortality, stroke
More informationPractical Considerations in the Early Treatment of Acute Stroke
Practical Considerations in the Early Treatment of Acute Stroke Matthew E. Fink, MD Neurologist-in-Chief Weill Cornell Medical College New York-Presbyterian Hospital mfink@med.cornell.edu Disclosures Consultant
More informationAppendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
More informationAdvances in Neuro-Endovascular Care for Acute Stroke
Advances in Neuro-Endovascular Care for Acute Stroke Ciarán J. Powers, MD, PhD, FAANS Associate Professor Program Director Department of Neurological Surgery Surgical Director Comprehensive Stroke Center
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationCryptogenic Stroke: The role of silent Atrial Fibrillation
Cryptogenic Stroke: The role of silent Atrial Fibrillation PD Dr. med. Martin A. Ritter Westfälische Wilhelms-Universität Münster Germany ritterm@uni-muenster.de 1 Turin, 25.10.2014 Agenda 1. What is a
More informationAlan Barber. Professor of Clinical Neurology University of Auckland
Alan Barber Professor of Clinical Neurology University of Auckland Presented with Non-fluent dysphasia R facial weakness Background Ischaemic heart disease Hypertension Hyperlipidemia L MCA branch
More informationIs Stroke a Paradoxical Embolism in Patients with Patent Foramen Ovale?
ORIGINAL ARTICLE Is Stroke a Paradoxical Embolism in Patients with Patent Foramen Ovale? Masahiro YASAKA, Ryoichi OTSUBO, Hiroshi OE and Kazuo MINEMATSU Abstract Objective Purpose was to assess the stroke
More informationAn international, double-blind, phase III randomized trial. Main Results
An international, double-blind, phase III randomized trial Main Results Robert Hart on behalf of the NAVIGATE ESUS Steering Committee and Investigators Sponsorship & Disclosures NAVIGATE ESUS was sponsored
More informationShould We Reconsider using Anticoagulation for Biological Tissue Valves
Should We Reconsider using Anticoagulation for Biological Tissue Valves No Disclosures Disclosures Watching grass grow Complete with audio 1 hour 8 minutes 9884 views Subclinical Leaflet Thrombosis in
More information